ArticleHuman vaccines & immunotherapeutics2026
Costs of managing adverse reactions to hexavalent vaccines: Comparison of DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib in France and Spain.
George Nikitas et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.